We are live on ! Find out more
ODT

Odonate Therapeutics, Inc. Common Stock

Delisted

ODT was delisted on the 14th of January, 2022.

89 hedge funds and large institutions have $495M invested in Odonate Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 41 increasing their positions, 16 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 16

118% more call options, than puts

Call options by funds: $4M | Put options by funds: $1.83M

6% less funds holding

Funds holding: 9589 (-6)

21% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 29

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

62% less capital invested

Capital invested by funds: $1.29B → $495M (-$800M)

Holders
89
Holders Change
-6
Holders Change %
-6.32%
% of All Funds
1.8%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
23
Increased
41
Reduced
16
Closed
29
Calls
$4M
Puts
$1.83M
Net Calls
+$2.17M
Net Calls Change
+$4.47M
Name Holding Trade Value Shares
Change
Change in
Stake
TCM
1
Tang Capital Management
California
$205M +$33M +1,163,513 +8%
BC
2
Boxer Capital
California
$69.9M +$52.2M +1,843,709 +55%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$60.9M +$72.4M +2,555,217 +129%
Janus Henderson Group
4
Janus Henderson Group
United Kingdom
$35.3M +$27.6M +974,750 +59%
DCM
5
Driehaus Capital Management
Illinois
$15.7M +$10.9M +385,622 +49%
RI
6
RTW Investments
New York
$13.4M +$14.7M +518,229 +108%
BlackRock
7
BlackRock
New York
$12.1M +$74.4K +2,627 +0.3%
SB
8
Samsara BioCapital
California
$11M +$9.03M +318,916 +64%
Vanguard Group
9
Vanguard Group
Pennsylvania
$10.3M +$2.5M +88,100 +13%
RSCM
10
Rock Springs Capital Management
Maryland
$6.57M +$1.48M +52,201 +12%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$6.18M -$16.1M -568,979 -55%
Two Sigma Investments
12
Two Sigma Investments
New York
$4.21M +$8.89M +313,771 New
Invesco
13
Invesco
Georgia
$3.42M -$585K -20,641 -8%
State Street
14
State Street
Massachusetts
$3.34M +$42K +1,481 +0.6%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$2.68M +$79.3K +2,799 +1%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$2.32M +$4.16M +147,000 +572%
Assenagon Asset Management
17
Assenagon Asset Management
Luxembourg
$2.31M +$3.38M +119,435 +229%
Northern Trust
18
Northern Trust
Illinois
$2.2M -$72.7K -2,567 -2%
SCM
19
Sio Capital Management
New York
$1.81M +$3.82M +135,000 New
Arrowstreet Capital
20
Arrowstreet Capital
Massachusetts
$1.68M +$3.37M +118,893 +1,881%
Citadel Advisors
21
Citadel Advisors
Florida
$1.64M +$2.16M +76,090 +166%
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$1.38M +$39K +1,378 +1%
Voloridge Investment Management
23
Voloridge Investment Management
Florida
$1.22M +$2.57M +90,575 New
Charles Schwab
24
Charles Schwab
California
$1.18M +$177K +6,234 +8%
EGM
25
Engineers Gate Manager
New York
$1.17M +$2.46M +86,971 New

ODT Hedge Fund Activity: Q3 2020 in Review

89 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q3 2020, worth a combined $495M — down 62% from $1.29B a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of ODT and 23 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 41 added.

The largest buyer was Wellington Management Group, adding an estimated $72.4M. The largest seller was Franklin Resources, cutting an estimated $29.6M.

  • 89 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q3 2020, down from 95 in Q2 2020.
  • Funds reported $495M of Odonate Therapeutics, Inc. Common Stock stock for Q3 2020, down 62% quarter-over-quarter.
  • 23 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q3 2020 and 29 closed out, a net change of -6 holders.
  • The largest Odonate Therapeutics, Inc. Common Stock buyer in Q3 2020 was Wellington Management Group, an estimated $72.4M added.
  • The largest Odonate Therapeutics, Inc. Common Stock seller in Q3 2020 was Franklin Resources, an estimated $29.6M sold.

Based on aggregated 13F filings for Q3 2020.